{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T21:11:06Z","timestamp":1776114666612,"version":"3.50.1"},"reference-count":220,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Non-coding RNA Research"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ncrna.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T22:05:19Z","timestamp":1535666719000},"page":"161-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Relations between approved platinum drugs and non-coding RNAs in mesothelioma"],"prefix":"10.1016","volume":"3","author":[{"given":"Bernhard","family":"Biersack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncrna.2018.08.001_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/oemed-2017-104298","article-title":"Estimation of the global burden of mesothelioma deaths from incomplete national mortality data","volume":"74","author":"Odgerel","year":"2017","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.ncrna.2018.08.001_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1440-1843.2005.00714.x","article-title":"Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma","volume":"10","author":"Sterman","year":"2005","journal-title":"Respirology"},{"key":"10.1016\/j.ncrna.2018.08.001_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ncrna.2018.08.001_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8556","article-title":"Patterns of metastases in malignant pleural mesothelioma in the modern era: redefining the spread of an old disease","volume":"35","author":"Collins","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib7","author":"WHO","year":"2014","journal-title":"World Health Organization"},{"key":"10.1016\/j.ncrna.2018.08.001_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib9","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"10.1016\/j.ncrna.2018.08.001_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ncrna.2018.08.001_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1179\/2049396714Y.0000000087","article-title":"Asbestos-related occupational cancers compensated under the Spanish national insurance system, 1978-2011","volume":"21","author":"Garc\u00eda-G\u00f3mez","year":"2015","journal-title":"Int. J. Occup. Environ. Health"},{"key":"10.1016\/j.ncrna.2018.08.001_bib12","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1096\/fj.01-0150com","article-title":"5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor","volume":"15","author":"Romano","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.ncrna.2018.08.001_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2018.00091","article-title":"New perspectives on diagnosis and therapy of malignant pleural mesothelioma","volume":"8","author":"Rossini","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/2211536605666160128151018","article-title":"Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma","volume":"5","author":"Truini","year":"2016","journal-title":"MicroRNA"},{"key":"10.1016\/j.ncrna.2018.08.001_bib15","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s00018-014-1584-5","article-title":"Role of microRNAs in malignant mesothelioma","volume":"71","author":"Truini","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ncrna.2018.08.001_bib16","first-page":"182","article-title":"Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma","volume":"3","author":"Zhang","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ncrna.2018.08.001_bib17","first-page":"51","article-title":"New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials","volume":"7","author":"Kotova","year":"2015","journal-title":"Canc. Manag. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib18","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib19","article-title":"Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma","volume":"7","author":"Roe","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomized, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ncrna.2018.08.001_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib22","first-page":"1","article-title":"MicroRNAs as potential biomarkers in malignant pleural mesothelioma","volume":"6","author":"Santoni-Rugiu","year":"2016","journal-title":"Curr. Biomark. Find."},{"key":"10.1016\/j.ncrna.2018.08.001_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.gdata.2016.06.009","article-title":"MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients","volume":"9","author":"Lin","year":"2016","journal-title":"Genomics Data"},{"key":"10.1016\/j.ncrna.2018.08.001_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ncrna.2017.05.002","article-title":"Non-coding RNAs are promising targets for stem cell-based cancer therapy","volume":"2","author":"Sakamoto","year":"2017","journal-title":"Non-coding RNA Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ncrna.2016.10.001","article-title":"Interactions between anticancer active platinum complexes and non-coding RNAs\/microRNAs","volume":"2","author":"Biersack","year":"2017","journal-title":"Non-coding RNA Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartels","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ncrna.2018.08.001_bib27","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1038\/onc.2010.34","article-title":"Multiple microRNAs modulate p21Cip1\/Waf1 expression by directly targeting its 3\u2018 untranslated region","volume":"29","author":"Wu","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ncrna.2018.08.001_bib28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib29","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib30","first-page":"42","article-title":"Roles, functions, and mechanisms of long non-coding RNAs in cancer","volume":"14","author":"Fang","year":"2016","journal-title":"Dev. Reprod. Biol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4161\/rna.20481","article-title":"The hallmarks of cancer: a long non-coding RNA point of view","volume":"9","author":"Gutschner","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ncrna.2018.04.001","article-title":"Crosstalk mechanisms between the WNT signaling pathway and long non-coding RNAs","volume":"3","author":"Zarkou","year":"2018","journal-title":"Non-coding RNA Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/222385a0","article-title":"Platinum compounds: a new class of potent antitumour agents","volume":"222","author":"Rosenberg","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.ncrna.2018.08.001_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/pauz.200500162","article-title":"Cisplatin und seine Analoga","volume":"35","author":"Voigt","year":"2006","journal-title":"Pharmazie Unserer Zeit"},{"key":"10.1016\/j.ncrna.2018.08.001_bib35","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, recognition, and processing of cisplatin-DNA adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ncrna.2018.08.001_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ncrna.2018.08.001_bib37","doi-asserted-by":"crossref","first-page":"A17","DOI":"10.1186\/1897-4287-10-S4-A17","article-title":"Cisplatin in breast cancer treatment in BRCA1 carriers","volume":"10","author":"Gronwald","year":"2012","journal-title":"Hered. Cancer Clin. Pract."},{"key":"10.1016\/j.ncrna.2018.08.001_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0027-5107(01)00141-5","article-title":"Mechanisms of resistance to cisplatin","volume":"478","author":"Kartalou","year":"2001","journal-title":"Mutat. Res. Fund Mol. Mech. Mutagen"},{"key":"10.1016\/j.ncrna.2018.08.001_bib39","series-title":"Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies","first-page":"55","volume":"12","author":"Oh","year":"2014"},{"key":"10.1016\/j.ncrna.2018.08.001_bib40","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1007\/s13277-015-4081-z","article-title":"Overexpression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells","volume":"37","author":"Samuel","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.canlet.2013.09.034","article-title":"MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9","volume":"343","author":"Dong","year":"2014","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ncrna.2018.08.001_bib42","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/cddis.2010.85","article-title":"Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells","volume":"1","author":"Bhatnagar","year":"2010","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ncrna.2018.08.001_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.omtn.2017.07.001","article-title":"MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma","volume":"8","author":"Moody","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ncrna.2018.08.001_bib44","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jmoldx.2014.03.002","article-title":"Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma","volume":"16","author":"Andersen","year":"2014","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ncrna.2018.08.001_bib45","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0959-8049(13)70145-X","article-title":"MC13-0031 Tumour miR-210 expression is elevated in malignant pleural mesothelioma patients with shorter survival undergoing extrapleural pneumonectomy","volume":"49","author":"Kirschner","year":"2013","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib46","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1590\/1414-431X20131662","article-title":"Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells","volume":"46","author":"Yin","year":"2013","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib47","doi-asserted-by":"crossref","first-page":"68627","DOI":"10.18632\/oncotarget.19800","article-title":"Downregulation of miR-99a\/let-7c\/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma","volume":"8","author":"Truini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ncrna.2018.08.001_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2013.08.030","article-title":"MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3","volume":"342","author":"Zhao","year":"2014","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ncrna.2018.08.001_bib49","first-page":"955","article-title":"Let-7c sensitizes acquired cisplatin-resistance A549 cells by targeting ABCC2 and Bcl-XL","volume":"68","author":"Zhan","year":"2013","journal-title":"Pharmazie"},{"key":"10.1016\/j.ncrna.2018.08.001_bib50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1756-8722-6-77","article-title":"Inhibition of hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs","volume":"6","author":"Ahmad","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1757-2215-4-17","article-title":"MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines","volume":"4","author":"Kumar","year":"2011","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib52","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-12-0701","article-title":"Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6\/STAT3 pathway in esophageal squamous cell carcinoma","volume":"18","author":"Sugimura","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib53","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9645940","article-title":"MicroRNA expression in malignant pleural mesothelioma and asbestosis: a pilot study","volume":"2017","author":"Mozzoni","year":"2017","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ncrna.2018.08.001_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181270","article-title":"The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer","volume":"12","author":"Goto","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12033-014-9796-3","article-title":"MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells","volume":"57","author":"Yin","year":"2015","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib56","article-title":"MiR-451 selectively increases sensitivity to cisplatin in ERCC1-high non-small cell lung cancer cells","author":"Liu","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ncrna.2018.08.001_bib57","doi-asserted-by":"crossref","first-page":"17300","DOI":"10.18632\/oncotarget.24644","article-title":"MiR-21 overexpression and programmed cell death 4 down-regulation features malignant pleural mesothelioma","volume":"9","author":"Nicol\u00e8","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ncrna.2018.08.001_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4161\/cbt.19073","article-title":"MiRNA-21 \u2013 a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer","volume":"13","author":"Gao","year":"2012","journal-title":"Canc. Biol. Ther."},{"key":"10.1016\/j.ncrna.2018.08.001_bib59","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3892\/or.2013.2351","article-title":"Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells","volume":"29","author":"Tanaka","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-016-0387-6","article-title":"Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET an AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism","volume":"10","author":"El Bizawy","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-4598-13-8","article-title":"Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy","volume":"13","author":"Li","year":"2014","journal-title":"Mol. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib62","doi-asserted-by":"crossref","first-page":"E3553","DOI":"10.1073\/pnas.1412686111","article-title":"Small RNA combination therapy for lung cancer","volume":"111","author":"Xue","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ncrna.2018.08.001_bib63","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1007\/s13277-014-2284-3","article-title":"Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells","volume":"35","author":"Yu","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib64","first-page":"45","article-title":"MicroRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status, Cancer Biother","volume":"28","author":"Wang","year":"2013","journal-title":"Radiopharm"},{"key":"10.1016\/j.ncrna.2018.08.001_bib65","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1158\/1078-0432.CCR-10-3040","article-title":"Epigenetic silencing of microRNA-34b\/c plays an important role in the pathogenesis of malignant pleural mesothelioma","volume":"17","author":"Kubo","year":"2011","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib66","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.1158\/1078-0432.CCR-13-0736","article-title":"Epigenetic inactivation of microRNA-34b\/c predicts poor disease-free survival in early stage lung adenocarcinoma","volume":"19","author":"Nadal","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib67","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/1541-7786.MCR-14-0442","article-title":"Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma","volume":"13","author":"Birnie","year":"2015","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib68","article-title":"MicroRNA-223 increases the sensitivity of triple-negative breast cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib69","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.25285","article-title":"Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma","volume":"127","author":"Gee","year":"2010","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib70","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-011-1752-3","article-title":"MiR-200bc\/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP","volume":"69","author":"Zhu","year":"2012","journal-title":"Cancer Chemother. Pharmacol. (Basel)"},{"key":"10.1016\/j.ncrna.2018.08.001_bib71","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1541-7786.MCR-10-0052","article-title":"Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer","volume":"8","author":"Ceppi","year":"2010","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib72","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3892\/ijo.2016.3358","article-title":"Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma","volume":"48","author":"Amatya","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib73","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.febslet.2013.01.016","article-title":"miR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells","volume":"587","author":"Wang","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ncrna.2018.08.001_bib74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-07-2488","article-title":"MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN","volume":"68","author":"Yang","year":"2008","journal-title":"Canc. Res."},{"issue":"3 Suppl","key":"10.1016\/j.ncrna.2018.08.001_bib75","article-title":"Abstract B37: investigating the potential of miR-203 as a therapeutic candidate and its role in the pathobiology of malignant pleural mesothelioma (MPM)","volume":"18","author":"Suraokar","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib76","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3892\/or.2017.5505","article-title":"Overexpression of miR-203 increases the sensitivity of NSCLC A549\/H460 cell lines to cisplatin by targeting Dickkopf-1","volume":"37","author":"Cheng","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib77","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma \u2013 a miRNA microarray analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ncrna.2018.08.001_bib78","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/ijc.25191","article-title":"Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin","volume":"127","author":"Pogribny","year":"2010","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib79","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ncrna.2018.08.001_bib80","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0b013e31820db125","article-title":"MicroRNAs dysregulated in human malignant pleural mesothelioma","volume":"6","author":"Balatti","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib81","doi-asserted-by":"crossref","first-page":"A222","DOI":"10.1093\/ajcp\/142.suppl1.222","article-title":"MiRNA 148a is highly expressed in malignant mesothelioma","volume":"142","author":"Esebua","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib82","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3892\/ijo.2017.3851","article-title":"MiR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells","volume":"50","author":"Kim","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib83","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12032-010-9797-4","article-title":"MiR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2","volume":"29","author":"Zhu","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib84","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1378\/chest.12-2770","article-title":"MiR-1 induces growth arrest and apoptosis in malignant mesothelioma","volume":"144","author":"Xu","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ncrna.2018.08.001_bib85","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.3892\/or.2016.4714","article-title":"MiR-1-mediated paracrine effect of cancer-associated fibroblasts on lung cancer cell proliferation and chemoresistance","volume":"35","author":"Li","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib86","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/onc.2013.476","article-title":"Protumorigenic effects of miR-145 loss in malignant pleural mesothelioma","volume":"33","author":"Cioce","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.ncrna.2018.08.001_bib87","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/cts.12323","article-title":"Cisplatin and paclitaxel alter the expression pattern of miR-143\/145 and miR-183\/96\/182 clusters in T24 bladder cancer cells","volume":"8","author":"Papadopoulos","year":"2015","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ncrna.2018.08.001_bib88","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1007\/s13277-016-4957-6","article-title":"MiR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1","volume":"37","author":"Zhan","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ncrna.2018.08.001_bib89","first-page":"4585","article-title":"Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ncrna.2018.08.001_bib90","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/toxsci\/kfw077","article-title":"Detection of drug-induced acute kidney injury in humans using urinary KIM-1, miR-21, -200c, and -423","volume":"152","author":"Pavkovic","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ncrna.2018.08.001_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070940","article-title":"Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM)","volume":"8","author":"Wright","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib92","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/ijms19051297","article-title":"In silico and in vitro analyses of lncRNAs as potential regulators in the transition from the epitheloid to sarcomatoid histotype of malignant pleural mesothelioma (MPM)","volume":"19","author":"Singh","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ncrna.2018.08.001_bib93","article-title":"The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregulation of p21WAF1\/CIP1 expression","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib94","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.biopha.2018.02.130","article-title":"LncRNA-MALAT1 contributes tot he cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation","volume":"101","author":"Fang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ncrna.2018.08.001_bib95","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.18632\/oncotarget.13708","article-title":"Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ncrna.2018.08.001_bib96","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/JTO.0000000000000202","article-title":"Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma","volume":"9","author":"Riquelme","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib97","doi-asserted-by":"crossref","first-page":"15923","DOI":"10.1039\/C8RA00549D","article-title":"Long non-coding RNA CASC2 enhanced cisplatin-induced viability inhibition of non-small cell lung cancer cells by regulating the PTEN\/PI3K\/Akt pathway through down-regulation of miR-18a and miR-21","volume":"8","author":"Li","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.ncrna.2018.08.001_bib98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jphs.2015.04.003","article-title":"EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells","volume":"128","author":"Hu","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ncrna.2018.08.001_bib99","first-page":"4851","article-title":"Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells","volume":"32","author":"Mazumder","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib100","first-page":"5239","article-title":"Scientific opinion on the safety of green tea catechins","volume":"16","author":"Younes","year":"2018","journal-title":"EFSA J"},{"key":"10.1016\/j.ncrna.2018.08.001_bib101","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1182\/blood-2009-03-204776","article-title":"Bortezomib and EGCG: no green tea for you?","volume":"113","author":"Shah","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ncrna.2018.08.001_bib102","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molcel.2010.03.007","article-title":"Genome-wide dissection of microRNA functions and cotargeting networks using genes et signatures","volume":"38","author":"Tsang","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ncrna.2018.08.001_bib103","article-title":"Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1","author":"Zhu","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ncrna.2018.08.001_bib104","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11064-012-0936-5","article-title":"Overexpression of miR-7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells","volume":"38","author":"Chakrabarti","year":"2013","journal-title":"Neurochem. Res."},{"issue":"Suppl. 11","key":"10.1016\/j.ncrna.2018.08.001_bib105","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1471-2164-15-S11-S3","article-title":"Gene regulation mediated by microRNAs in response to green tea polyphenol EGCG in mouse lung cancer","volume":"15","author":"Zhou","year":"2014","journal-title":"BMC Genom."},{"key":"10.1016\/j.ncrna.2018.08.001_bib106","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1096\/fj.10-167924","article-title":"Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer","volume":"25","author":"Siddiqi","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.ncrna.2018.08.001_bib107","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/carcin\/bgr218","article-title":"Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1\u03b1","volume":"32","author":"Wang","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ncrna.2018.08.001_bib108","doi-asserted-by":"crossref","first-page":"43337","DOI":"10.18632\/oncotarget.9712","article-title":"NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ncrna.2018.08.001_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/6662579f-3a41-4bce-9298-9d15f6582ef5","article-title":"Up-regulation of microRNA-21 correlates with lower kidney cancer survival","volume":"7","author":"Zaman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3892\/ol.2011.460","article-title":"Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer","volume":"3","author":"Rhodes","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ncrna.2018.08.001_bib111","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/bcr3194","article-title":"MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis","volume":"14","author":"Chang","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib112","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1940-6207.CAPR-14-0357","article-title":"3,6-Dihydroxyflavone suppresses breast carcinogenesis by epigenetically regulating miR-34a and miR-21","volume":"8","author":"Chang","year":"2015","journal-title":"Canc. Prev. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib113","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/srep02459","article-title":"Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21\/low miR-200c signature in vivo","volume":"3","author":"Cufi","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib114","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2174\/138945012804545597","article-title":"Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells","volume":"13","author":"Xia","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ncrna.2018.08.001_bib115","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1159\/000374024","article-title":"The p53\/miR-34a\/SIRT1 positive feedback loop in quercetin-induced apoptosis","volume":"35","author":"Lou","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ncrna.2018.08.001_bib116","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/pros.23201","article-title":"Regulation of miR-200c and miR-141 by methylation in prostate cancer","volume":"76","author":"Lynch","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.ncrna.2018.08.001_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070372","article-title":"Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR","volume":"8","author":"Chiyomaru","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib118","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1159\/000369732","article-title":"Calycosin and genistein induce apoptosis by inactivation of HOTAIR\/p-Akt signaling pathway in human breast cancer MCF-7 cells","volume":"35","author":"Chen","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ncrna.2018.08.001_bib119","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.toxlet.2014.09.014","article-title":"Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells","volume":"231","author":"Ma","year":"2014","journal-title":"Toxicol. Lett"},{"key":"10.1016\/j.ncrna.2018.08.001_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030590","article-title":"Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling","volume":"7","author":"Subramaniam","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib121","first-page":"403","article-title":"Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells","volume":"9","author":"Mirgani","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ncrna.2018.08.001_bib122","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1158\/0008-5472.CAN-09-4598","article-title":"Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF","volume":"70","author":"Ali","year":"2010","journal-title":"Canc. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib123","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1940-6207.CAPR-11-0267","article-title":"Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer","volume":"4","author":"Saini","year":"2011","journal-title":"Canc. Prev. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib124","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/1471-2407-12-564","article-title":"Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (sp) transcription factors by targeting microRNAs","volume":"12","author":"Gandhy","year":"2012","journal-title":"BMC Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1042\/BSR20100065","article-title":"Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cells","volume":"31","author":"Mudduluru","year":"2011","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib126","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s12094-013-1135-9","article-title":"MiR-21 suppresses the anticancer activities of curcumin by targeting PTEN gene in human non-small cell lung cancer A549 cells","volume":"16","author":"Zhang","year":"2014","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib127","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.7314\/APJCP.2014.15.10.4239","article-title":"Influence of curcumin on HOTAIR-mediated migration of human renal cell carcinoma cells","volume":"15","author":"Pei","year":"2014","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ncrna.2018.08.001_bib128","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcb.21742","article-title":"Curcumin downregulates H19 gene transcription in tumor cells","volume":"104","author":"Kujundzic","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ncrna.2018.08.001_bib129","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/carcin\/bgx065","article-title":"Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression","volume":"38","author":"Yoshida","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ncrna.2018.08.001_bib130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017850","article-title":"Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer","volume":"6","author":"Bao","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib131","article-title":"Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF","volume":"7","author":"Bao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib132","article-title":"Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment","volume":"7","author":"Bao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib133","article-title":"The curcumin analog EF24 targets NF-\u03baB and miRNA-21, and has potent anticancer activity in vitro and in vivo","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib134","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.bcp.2010.07.003","article-title":"Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGF-beta signaling pathway in SW480 cells","volume":"80","author":"Tili","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12094-012-0999-4","article-title":"Resveratrol induces apoptosis of pancreatic cancer cells by inhibiting miR-21 regulation of Bcl-2 expression","volume":"15","author":"Liu","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib136","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jnutbio.2013.04.006","article-title":"Anti-cancer effects of naturally occurring compounds through modulation of signal transduction and miRNA expression in human colon cancer cells","volume":"24","author":"Kumazaki","year":"2013","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ncrna.2018.08.001_bib137","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1186\/s12885-015-1958-6","article-title":"Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo","volume":"15","author":"Yang","year":"2015","journal-title":"BMC Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib138","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/srep00314","article-title":"Stilbene derivatives promote AGO2-dependent tumour-suppressive micro-RNA activity","volume":"2","author":"Hagiwara","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib139","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-015-1718-0","article-title":"Altered expression of long non-coding RNAs during genotoxic stress-induced cell death in human glioma cells","volume":"122","author":"Liu","year":"2015","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib140","article-title":"Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt\/\u03b2-catenin signal pathway","volume":"11","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib141","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11010-013-1726-3","article-title":"Emodin can induce K562 cells to erythroid differentiation and improve expression of globin genes","volume":"382","author":"Ma","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ncrna.2018.08.001_bib142","first-page":"2085","article-title":"miR-211 and miR-429 are involved in emodin's anti-proliferative effects on lung cancer","volume":"9","author":"Ren","year":"2016","journal-title":"Int. J. Clin. Med."},{"key":"10.1016\/j.ncrna.2018.08.001_bib143","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.3892\/mmr.2015.4158","article-title":"Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-\u03b2\/drosophila mothers against decapentaplegic pathway and angiogenesis-associated micro-RNAs","volume":"12","author":"Lin","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib144","doi-asserted-by":"crossref","first-page":"16396","DOI":"10.18632\/oncotarget.3844","article-title":"Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-\u03b2-catenin signaling axis in a microRNA-34a dependent manner","volume":"6","author":"Avtanski","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ncrna.2018.08.001_bib145","doi-asserted-by":"crossref","first-page":"14697","DOI":"10.1038\/srep14697","article-title":"A robust screening method for dietary agents that activate tumour-suppressor microRNAs","volume":"5","author":"Hagiwara","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib146","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mnfr.201200297","article-title":"Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures","volume":"57","author":"Parasramka","year":"2013","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib147","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1158\/1535-7163.MCT-12-0232-T","article-title":"Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer","volume":"11","author":"Ahmad","year":"2012","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ncrna.2018.08.001_bib148","article-title":"The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib149","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.fob.2015.05.009","article-title":"Blockade of TGF\u03b2-SMAD2 by demethylation-activated miR-148a is involved in caffeic acid-induced inhibition of cancer stem cell-like properties in vitro and in vivo","volume":"5","author":"Li","year":"2015","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ncrna.2018.08.001_bib150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ptr.5267","article-title":"Antiproliferative effects of polyphenols from pomegranate rind (Punica granatum L.) on EJ bladder cancer cells via regulation of p53\/miR-34a axis","volume":"29","author":"Zhou","year":"2015","journal-title":"Phytother Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib151","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2165\/00003495-199039030-00008","article-title":"Etoposide. A review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer","volume":"39","author":"Henwood","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.ncrna.2018.08.001_bib152","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","article-title":"Etoposide: four decades of development of a topoisomerase II inhibitor","volume":"34","author":"Hande","year":"1998","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114757","article-title":"p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression","volume":"9","author":"Novello","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib154","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/bjc.1996.465","article-title":"Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC lung cancer cooperative group","volume":"74","author":"van Meerbeeck","year":"1996","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib155","first-page":"1001","article-title":"A case of malignant peritoneal mesothelioma successfully treated with carboplatin and paclitaxel","volume":"33","author":"Ogura","year":"2007","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ncrna.2018.08.001_bib156","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/rcr2.145","article-title":"Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma","volume":"4","author":"Kanai","year":"2016","journal-title":"Respirol. Case Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib157","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jcp.24730","article-title":"Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression","volume":"230","author":"Fr\u00e8res","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib158","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000334237","article-title":"MiR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment","volume":"81","author":"Ghawanmeh","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.ncrna.2018.08.001_bib159","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1742-7843.2012.00870.x","article-title":"Ursolic acid inhibits proliferation and induces apoptosis in human glioblastoma cell lines U251 by suppressing TGF-\u03b21\/miR-21\/PDCD4 pathway","volume":"111","author":"Wang","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib160","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/jid.2010.349","article-title":"MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in S\u00e9zary syndrome","volume":"131","author":"van der Fits","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib161","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/aps.2010.220","article-title":"Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128","volume":"32","author":"Wu","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ncrna.2018.08.001_bib162","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3892\/or.2012.2136","article-title":"Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells","volume":"29","author":"An","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib163","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/1940-6207.CAPR-14-0354","article-title":"Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer","volume":"8","author":"Toden","year":"2015","journal-title":"Canc. Prev. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib164","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/carcin\/bgs286","article-title":"Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family","volume":"33","author":"Takahashi","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ncrna.2018.08.001_bib165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-0500-3-24","article-title":"Non-coding RNAs change their expression profile after retinoid induced differentiation of the pro-myelocytic cell line NB4","volume":"3","author":"Rossi","year":"2010","journal-title":"BMC Res"},{"key":"10.1016\/j.ncrna.2018.08.001_bib166","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/sj.onc.1210186","article-title":"MicroRNA gene expression during retinoid acid-induced differentiation of human acute promyelocytic leukemia","volume":"26","author":"Garzon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ncrna.2018.08.001_bib167","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1002\/ijc.27549","article-title":"Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in non-small cell lung cancer cells","volume":"131","author":"Ji","year":"2012","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib168","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/carcin\/bgt255","article-title":"A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2\/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells","volume":"34","author":"Yeh","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ncrna.2018.08.001_bib169","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.biomaterials.2015.01.007","article-title":"PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a","volume":"51","author":"Bhattacharya","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ncrna.2018.08.001_bib170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ncrna.2016.09.001","article-title":"Non-coding RNA\/microRNA-modulatory dietary factors and natural products for improved cancer therapy and prevention: alkaloids, organosulfur compounds, aliphatic carboxylic acids and water-soluble vitamins","volume":"1","author":"Biersack","year":"2016","journal-title":"Non-coding RNA Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib171","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib172","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604421","article-title":"Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma","volume":"99","author":"Sorensen","year":"2008","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib173","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-04-0163","article-title":"Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice","volume":"10","author":"Anderton","year":"2004","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib174","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/carcin\/bgp208","article-title":"Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol","volume":"31","author":"Melkamu","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ncrna.2018.08.001_bib175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033729","article-title":"Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM","volume":"7","author":"Kong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib176","first-page":"432","article-title":"Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness","volume":"4","author":"Kashat","year":"2012","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054657","article-title":"3,3\u2019-Diindolylmethane enhances the effectiveness of herceptin against HER-2\/neu-expressing breast cancer cells","volume":"8","author":"Ahmad","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib178","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/13543784.13.3.269","article-title":"Camptothecins in clinical development","volume":"13","author":"Zunino","year":"2004","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ncrna.2018.08.001_bib179","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2009.01.014","article-title":"MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy","volume":"113","author":"Boren","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib180","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E","article-title":"Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma","volume":"85","author":"Nakano","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ncrna.2018.08.001_bib181","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1039\/C4NP00051J","article-title":"Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics","volume":"32","author":"Le","year":"2015","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib182","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/JCO.2017.35.15_suppl.8513","article-title":"Trabectedin (T) as a second line treatment option for patients with epithelioid malignant pleural mesothelioma (MPM) in progression following pemetrexed\/platin-derivates chemotherapy: ATREUS trial","volume":"35","author":"Cortinovis","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib183","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1200\/jco.2015.33.15_suppl.7561","article-title":"Activity and safety of trabectedin in patients with sarcomatoid\/biphasic malignant pleural mesothelioma (MPM)","volume":"33","author":"Cortinovis","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib184","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035423","article-title":"A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma","volume":"7","author":"Uboldi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib185","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1158\/1535-7163.MCT-15-0846","article-title":"Trabectedin is active against malignant pleural mesothelioma cell and xenograft models and synergizes with chemotherapy and Bcl-2 inhibition in vitro","volume":"15","author":"Hoda","year":"2016","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ncrna.2018.08.001_bib186","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/abbs\/gmt075","article-title":"Berberine sensitizes ovarian cancer cells to cisplatin through miR-21\/PDCD4 axis","volume":"45","author":"Liu","year":"2013","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ncrna.2018.08.001_bib187","doi-asserted-by":"crossref","first-page":"14697","DOI":"10.1038\/srep14697","article-title":"A robust screening method for dietary agents that activate tumour-suppressor microRNAs","volume":"5","author":"Hagiwara","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00227","article-title":"Epigeneitc impacts of aascorbate on human metastatic melanoma cells","volume":"4","author":"Venturelli","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib189","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/carcin\/bgs198","article-title":"MiR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression","volume":"33","author":"Mandal","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ncrna.2018.08.001_bib190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1940-6207.CAPR-09-0202","article-title":"Chemoprevention of cigarette smoke-induced alterations of microRNA expression in rat lungs","volume":"3","author":"Izzotti","year":"2010","journal-title":"Canc. Prev. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112720","article-title":"Diallyl sulfide suppresses SRC\/Ras\/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib192","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3892\/ol.2016.4266","article-title":"Upregulation of miR-34a by diallyl disulfide suppresses invasion and induces apoptosis in SCG-7901 cells through inhibition of the PI3K\/Akt signaling pathway","volume":"11","author":"Wang","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ncrna.2018.08.001_bib193","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/01635581.2013.756530","article-title":"Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer","volume":"65","author":"Slaby","year":"2013","journal-title":"Nutr. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib194","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2013.06.027","article-title":"Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22","volume":"340","author":"Tang","year":"2013","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ncrna.2018.08.001_bib195","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jnutbio.2012.08.004","article-title":"Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2\/MMP2\/Snail, ZEB1 and miR-200c\/ZEB1 pathways in human bladder cancer cells","volume":"24","author":"Shan","year":"2013","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ncrna.2018.08.001_bib196","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ncrna.2018.08.001_bib197","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ncrna.2018.08.001_bib198","first-page":"983","article-title":"Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K\/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101","volume":"93","author":"Ferreira","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib199","first-page":"10","article-title":"The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells","volume":"27","author":"Rhodes","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ncrna.2018.08.001_bib200","first-page":"168949","article-title":"Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells, Biomed","volume":"2014","author":"Chu","year":"2014","journal-title":"Res. Intell."},{"key":"10.1016\/j.ncrna.2018.08.001_bib201","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/ijc.25162","article-title":"MiR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer","volume":"127","author":"Rauhala","year":"2010","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ncrna.2018.08.001_bib202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2013.05.061","article-title":"Epigenetic regulation of microRNA expression in renal cell carcinoma","volume":"436","author":"Schiffgen","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ncrna.2018.08.001_bib203","article-title":"MiR-449 and HDAC modulates HOTAIR expression which predicts poor prognosis in resected gastro-esophageal adenocarcinomas and doubles proliferation rate in HFE145 cells","volume":"3","author":"Stickertson","year":"2017","journal-title":"J. Gastric Discord. Ther."},{"key":"10.1016\/j.ncrna.2018.08.001_bib204","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.febslet.2011.06.025","article-title":"Epigenetic regulation of microRNA-375 and its role in melanoma development in humans","volume":"585","author":"Mazar","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ncrna.2018.08.001_bib205","first-page":"45","article-title":"Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells","volume":"24","author":"Lee","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ncrna.2018.08.001_bib206","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1074\/jbc.M114.624361","article-title":"MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cell senescence","volume":"290","author":"Cho","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ncrna.2018.08.001_bib207","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1590\/1414-431X20131662","article-title":"Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer HEp-2 cells","volume":"46","author":"Yin","year":"2013","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ncrna.2018.08.001_bib208","doi-asserted-by":"crossref","first-page":"19601","DOI":"10.18632\/oncotarget.7481","article-title":"MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes","volume":"7","author":"Zhong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ncrna.2018.08.001_bib209","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib210","doi-asserted-by":"crossref","first-page":"73257","DOI":"10.18632\/oncotarget.12304","article-title":"An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells","volume":"7","author":"Tang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ncrna.2018.08.001_bib211","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"5","author":"Dasasri","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ncrna.2018.08.001_bib212","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/201367","article-title":"Cellular response to cisplatin-induced DNA damage","volume":"2010","author":"Basu","year":"2010","journal-title":"J. Nucleic Acids"},{"key":"10.1016\/j.ncrna.2018.08.001_bib213","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4161\/cc.8.5.7753","article-title":"MiR-34, SIRT1 and p53: the feedback loop","volume":"8","author":"Yamaguchi","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ncrna.2018.08.001_bib214","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","article-title":"The miR-34 family in cancer and apoptosis","volume":"17","author":"Hermeking","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ncrna.2018.08.001_bib215","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1038\/mtna.2014.47","article-title":"Mir-34: a new weapon against cancer?","volume":"3","author":"Misso","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ncrna.2018.08.001_bib216","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090005","article-title":"In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPS) against multiple myeloma","volume":"9","author":"Di Martino","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2018.08.001_bib217","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ncrna.2018.08.001_bib218","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/adhm.201400222","article-title":"Degradable hyaluronic acid\/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy","volume":"4","author":"Wang","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ncrna.2018.08.001_bib219","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.biomaterials.2012.12.016","article-title":"Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model","volume":"34","author":"Hu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ncrna.2018.08.001_bib220","first-page":"S397","article-title":"Malignant pleural mesothelioma: current and future perspectives","volume":"5","author":"Porpodis","year":"2013","journal-title":"J. Thorac. Dis."}],"updated-by":[{"DOI":"10.1016\/j.ncrna.2020.11.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000}}],"container-title":["Non-coding RNA Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468054018300763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468054018300763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T18:29:23Z","timestamp":1751826563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468054018300763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":220,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S2468054018300763"],"URL":"https:\/\/doi.org\/10.1016\/j.ncrna.2018.08.001","relation":{},"ISSN":["2468-0540"],"issn-type":[{"value":"2468-0540","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relations between approved platinum drugs and non-coding RNAs in mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Non-coding RNA Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncrna.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}